BRAF and metastatic melanoma: The most frequent mutation found in around 90% of cases is V600 E. The discovery of vemurafenib (PLX4032) as a highly specific BRAFV600 E kinase inhibitor and its FDA-approval for treatment of BRAF mutant metastatic melanoma patients has changed the natural history of melanoma [4].